Hematologic data for patients with chronic active EBV seen at NIH
| Pt . | CD4% . | CD8% . | CD19% . | CD20% . | NK% . | EBV VCA IgG titer . | EBV load* . | Serum IgG . | |
|---|---|---|---|---|---|---|---|---|---|
| High . | Low . | ||||||||
| Unknown whether B-, T-, or NK- cell disease | |||||||||
| 1 | ND | ND | ND | ND | ND | 20 480 | ND | 2830 | 540 |
| 2 | 60 | 30 | 0 | 0.1 | 5.5 | 40 960 | ND | 5440 | 504 |
| 4 | 50 | 21 | ND | ND | 10 | 2560 | ND | 3080 | 682 |
| 5 | 20 | 45 | 5.6 | 4.6 | 0.7 | 1280 | ND | 3148 | 745 |
| B-cell disease | |||||||||
| 3 | 59 | 38 | 0.3 | 0.5 | 3 | 20 480 | ND | 3570 | 907 |
| 6 | 83 | 12 | 0 | 0 | 1.2 | 10 240 | ND | 914 | 756 |
| 7 | 22 | 59 | 2.9 | 2.9 | 16.4 | 20 480 | ND | 2680 | 328 |
| 8 | 22 | 23 | 13 | 6 | 16 | 2560 | 1:1000† | 1640 | 617 |
| 9 | 79 | 13 | 0.5 | 0.5 | 1.5 | 2560 | 1:10‡ | 2180 | 225 |
| 11 | 50 | 41 | ND | ND | 7 | 163 840 | 1:100§ | 6530 | ND |
| 12 | 56 | 36 | 0.8 | 0.7 | 5 | 640 | 5.0 × 105 | 643 | 479 |
| 13 | 64 | 8 | 17 | ND | 5 | ND | 1.7 × 106 | 734 | ND |
| 14 | 25 | 55 | 11 | 10 | 5.1 | 1280 | 5.7 × 103 | 793 | 553 |
| 16 | 42 | 32 | 5 | 5 | 17 | 320 | 4.6 × 104 | 916 | 910 |
| 17 | ND | ND | ND | ND | ND | > 10 240 | 2.2 × 106 | 432 | ND |
| T-cell disease | |||||||||
| 10 | 43 | 24 | 21 | 21 | 8 | 40 960 | 1:10 000¶ | 2330 | 2120 |
| 15 | 24 | 59 | 8 | ND | 4 | ND | 3.2 × 105 | 1910 | ND |
| 18 | ND | ND | ND | ND | ND | > 10 240 | 1.2 × 105 | 824 | ND |
| NK-cell disease | |||||||||
| 19 | 23 | 14 | 16 | ND | 47 | 320 | > 2.6 × 105 | 1010 | 817 |
| Pt . | CD4% . | CD8% . | CD19% . | CD20% . | NK% . | EBV VCA IgG titer . | EBV load* . | Serum IgG . | |
|---|---|---|---|---|---|---|---|---|---|
| High . | Low . | ||||||||
| Unknown whether B-, T-, or NK- cell disease | |||||||||
| 1 | ND | ND | ND | ND | ND | 20 480 | ND | 2830 | 540 |
| 2 | 60 | 30 | 0 | 0.1 | 5.5 | 40 960 | ND | 5440 | 504 |
| 4 | 50 | 21 | ND | ND | 10 | 2560 | ND | 3080 | 682 |
| 5 | 20 | 45 | 5.6 | 4.6 | 0.7 | 1280 | ND | 3148 | 745 |
| B-cell disease | |||||||||
| 3 | 59 | 38 | 0.3 | 0.5 | 3 | 20 480 | ND | 3570 | 907 |
| 6 | 83 | 12 | 0 | 0 | 1.2 | 10 240 | ND | 914 | 756 |
| 7 | 22 | 59 | 2.9 | 2.9 | 16.4 | 20 480 | ND | 2680 | 328 |
| 8 | 22 | 23 | 13 | 6 | 16 | 2560 | 1:1000† | 1640 | 617 |
| 9 | 79 | 13 | 0.5 | 0.5 | 1.5 | 2560 | 1:10‡ | 2180 | 225 |
| 11 | 50 | 41 | ND | ND | 7 | 163 840 | 1:100§ | 6530 | ND |
| 12 | 56 | 36 | 0.8 | 0.7 | 5 | 640 | 5.0 × 105 | 643 | 479 |
| 13 | 64 | 8 | 17 | ND | 5 | ND | 1.7 × 106 | 734 | ND |
| 14 | 25 | 55 | 11 | 10 | 5.1 | 1280 | 5.7 × 103 | 793 | 553 |
| 16 | 42 | 32 | 5 | 5 | 17 | 320 | 4.6 × 104 | 916 | 910 |
| 17 | ND | ND | ND | ND | ND | > 10 240 | 2.2 × 106 | 432 | ND |
| T-cell disease | |||||||||
| 10 | 43 | 24 | 21 | 21 | 8 | 40 960 | 1:10 000¶ | 2330 | 2120 |
| 15 | 24 | 59 | 8 | ND | 4 | ND | 3.2 × 105 | 1910 | ND |
| 18 | ND | ND | ND | ND | ND | > 10 240 | 1.2 × 105 | 824 | ND |
| NK-cell disease | |||||||||
| 19 | 23 | 14 | 16 | ND | 47 | 320 | > 2.6 × 105 | 1010 | 817 |
Normal values are CD4 362-1275 (29%-57%), CD8 344-911 (25%-51%), CD19 47-409 (3.5%-17%), CD20 49-424 (3.7%-16%), and CD56 87-505 (4.6%-30%); normal values for serum IgG for patients 1-16 at NIH are 642-1730 mg/dL, and for patients 17-19 at Baylor College of Medicine are 641-1353 mg/dL.
ND indicates not done; NIH, National Institutes of Health; Pt, patient; and VCA, dilution of antibody to EBV viral capsid antigen that is positive in the serum.
All laboratory data are shown before rituximab therapy given; low IgG and low CD19% were present before cytotoxic chemotherapy was given except for patient 3.
EBV load expressed as dilution of peripheral blood lymphocytes in which EBV PCR is positive (patients 8-11) or EBV copies per 106 genomes from PBMCs (patients 12-16) or EBV copies per μg of DNA (patients 17-19). The lower limit of detection was 10 EBV copies per 106 cellular genomes (assay used for patients 12-16) and 4 genomes of EBV per μg of DNA (assay used for patients 17-19).
Estimated to be ∼ 11 000 copies/mL.
Estimated to be ∼ 1200 copies/mL.
Estimated to be ∼ 4400 copies/mL.
Estimated to be > 11 000 copies/mL.